neo laboratories limited
neo laboratories limited Company Information
Company Number
00587959
Next Accounts
Sep 2025
Shareholders
simon robert geoffrey tate
charlotte emma mary tate
Group Structure
View All
Industry
Manufacture of basic pharmaceutical products
Registered Address
29a crown street, brentwood, essex, CM14 4BA
Website
www.neobarbican.comneo laboratories limited Estimated Valuation
Pomanda estimates the enterprise value of NEO LABORATORIES LIMITED at £1.8m based on a Turnover of £1.3m and 1.36x industry multiple (adjusted for size and gross margin).
neo laboratories limited Estimated Valuation
Pomanda estimates the enterprise value of NEO LABORATORIES LIMITED at £96.2k based on an EBITDA of £16.8k and a 5.73x industry multiple (adjusted for size and gross margin).
neo laboratories limited Estimated Valuation
Pomanda estimates the enterprise value of NEO LABORATORIES LIMITED at £253k based on Net Assets of £142k and 1.78x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Neo Laboratories Limited Overview
Neo Laboratories Limited is a live company located in essex, CM14 4BA with a Companies House number of 00587959. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in July 1957, it's largest shareholder is simon robert geoffrey tate with a 92% stake. Neo Laboratories Limited is a mature, small sized company, Pomanda has estimated its turnover at £1.3m with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Neo Laboratories Limited Health Check
Pomanda's financial health check has awarded Neo Laboratories Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 4 areas for improvement. Company Health Check FAQs
1 Strong
3 Regular
4 Weak
Size
annual sales of £1.3m, make it smaller than the average company (£37m)
- Neo Laboratories Limited
£37m - Industry AVG
Growth
3 year (CAGR) sales growth of 3%, show it is growing at a slower rate (5.2%)
- Neo Laboratories Limited
5.2% - Industry AVG
Production
with a gross margin of 38.3%, this company has a comparable cost of product (38.3%)
- Neo Laboratories Limited
38.3% - Industry AVG
Profitability
an operating margin of 1.3% make it less profitable than the average company (6.8%)
- Neo Laboratories Limited
6.8% - Industry AVG
Employees
with 3 employees, this is below the industry average (111)
3 - Neo Laboratories Limited
111 - Industry AVG
Pay Structure
on an average salary of £67.7k, the company has an equivalent pay structure (£67.7k)
- Neo Laboratories Limited
£67.7k - Industry AVG
Efficiency
resulting in sales per employee of £445.7k, this is equally as efficient (£445.7k)
- Neo Laboratories Limited
£445.7k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Neo Laboratories Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Neo Laboratories Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Neo Laboratories Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Neo Laboratories Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 2.7%, this is a lower level of debt than the average (44.8%)
2.7% - Neo Laboratories Limited
44.8% - Industry AVG
NEO LABORATORIES LIMITED financials
Neo Laboratories Limited's latest turnover from December 2023 is estimated at £1.3 million and the company has net assets of £142 thousand. According to their latest financial statements, Neo Laboratories Limited has 3 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | May 2016 | May 2015 | May 2014 | May 2013 | May 2012 | May 2011 | May 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | |||||||||||||||
| Tax | |||||||||||||||
| Profit After Tax | |||||||||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | |||||||||||||||
| Employee Costs | |||||||||||||||
| Number Of Employees | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | May 2016 | May 2015 | May 2014 | May 2013 | May 2012 | May 2011 | May 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | |||||||||||||||
| Intangible Assets | 504 | 576 | 670 | 128 | 212 | 296 | 380 | 464 | 512 | 596 | 680 | 425 | 44 | 86 | 128 |
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 504 | 576 | 670 | 128 | 212 | 296 | 380 | 464 | 512 | 596 | 680 | 425 | 44 | 86 | 128 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 33,285 | 32,857 | 50,922 | 36,349 | 28,598 | 18,998 | 10,824 | ||||||||
| Group Debtors | 72,607 | ||||||||||||||
| Misc Debtors | 145,316 | 129,676 | 77,617 | 302 | 75,878 | ||||||||||
| Cash | 2 | 48,971 | 49,471 | 133,127 | 65,997 | 8,565 | 113,619 | 85,847 | 24,666 | 33 | 8,566 | ||||
| misc current assets | |||||||||||||||
| total current assets | 145,316 | 129,678 | 126,588 | 122,380 | 133,127 | 99,282 | 84,443 | 113,619 | 85,847 | 57,523 | 50,955 | 44,915 | 28,598 | 18,998 | 10,824 |
| total assets | 145,820 | 130,254 | 127,258 | 122,508 | 133,339 | 99,578 | 84,823 | 114,083 | 86,359 | 58,119 | 51,635 | 45,340 | 28,642 | 19,084 | 10,952 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 3,029 | 45,205 | 21,216 | 1,700 | 2,018 | 3,794 | 2,273 | 1,808 | 547 | ||||||
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 3,859 | 840 | 1,426 | 2,756 | 25,338 | 3,379 | |||||||||
| total current liabilities | 3,859 | 840 | 1,426 | 2,756 | 25,338 | 3,379 | 3,029 | 45,205 | 21,216 | 1,700 | 2,018 | 3,794 | 2,273 | 1,808 | 547 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 3,859 | 840 | 1,426 | 2,756 | 25,338 | 3,379 | 3,029 | 45,205 | 21,216 | 1,700 | 2,018 | 3,794 | 2,273 | 1,808 | 547 |
| net assets | 141,961 | 129,414 | 125,832 | 119,752 | 108,001 | 96,199 | 81,794 | 68,878 | 65,143 | 56,419 | 49,617 | 41,546 | 26,369 | 17,276 | 10,405 |
| total shareholders funds | 141,961 | 129,414 | 125,832 | 119,752 | 108,001 | 96,199 | 81,794 | 68,878 | 65,143 | 56,419 | 49,617 | 41,546 | 26,369 | 17,276 | 10,405 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | May 2016 | May 2015 | May 2014 | May 2013 | May 2012 | May 2011 | May 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | |||||||||||||||
| Amortisation | 72 | 94 | 181 | 84 | 84 | 84 | 84 | 48 | 84 | 84 | 42 | 42 | 42 | 42 | |
| Tax | |||||||||||||||
| Stock | |||||||||||||||
| Debtors | 15,640 | 52,059 | 4,708 | 72,909 | -33,285 | -42,593 | 75,878 | -32,857 | -32,857 | -18,065 | 14,573 | 7,751 | 9,600 | 8,174 | 10,824 |
| Creditors | -3,029 | -42,176 | 43,505 | 19,516 | -318 | -1,776 | 1,521 | 465 | 1,261 | 547 | |||||
| Accruals and Deferred Income | 3,019 | -586 | -1,330 | -22,582 | 21,959 | 3,379 | |||||||||
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | |||||||||||||||
| cash and cash equivalents | |||||||||||||||
| cash | -2 | -48,969 | -500 | -83,656 | 67,130 | 57,432 | -105,054 | 88,953 | 61,181 | 24,633 | -8,533 | 8,566 | |||
| overdraft | |||||||||||||||
| change in cash | -2 | -48,969 | -500 | -83,656 | 67,130 | 57,432 | -105,054 | 88,953 | 61,181 | 24,633 | -8,533 | 8,566 |
neo laboratories limited Credit Report and Business Information
Neo Laboratories Limited Competitor Analysis
Perform a competitor analysis for neo laboratories limited by selecting its closest rivals, whether from the MANUFACTURING sector, other small companies, companies in CM14 area or any other competitors across 12 key performance metrics.
neo laboratories limited Ownership
NEO LABORATORIES LIMITED group structure
Neo Laboratories Limited has no subsidiary companies.
Ultimate parent company
NEO LABORATORIES LIMITED
00587959
neo laboratories limited directors
Neo Laboratories Limited currently has 3 directors. The longest serving directors include Mr Richard Warriner (Dec 1996) and Mrs Mary Tate (Jun 1999).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Richard Warriner | United Kingdom | 68 years | Dec 1996 | - | Director |
| Mrs Mary Tate | United Kingdom | 80 years | Jun 1999 | - | Director |
| Mr Simon Tate | United Kingdom | 47 years | Jun 1999 | - | Director |
P&L
December 2023turnover
1.3m
+5%
operating profit
16.7k
0%
gross margin
38.4%
+1.99%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
142k
+0.1%
total assets
145.8k
+0.12%
cash
0
-1%
net assets
Total assets minus all liabilities
neo laboratories limited company details
company number
00587959
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
July 1957
age
68
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
MOULTON JOHNSON LIMITED
auditor
-
address
29a crown street, brentwood, essex, CM14 4BA
Bank
-
Legal Advisor
-
neo laboratories limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to neo laboratories limited.
neo laboratories limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NEO LABORATORIES LIMITED. This can take several minutes, an email will notify you when this has completed.
neo laboratories limited Companies House Filings - See Documents
| date | description | view/download |
|---|
